24006-29-9

Upstream product

• 2144-08-3 2,3,4-trihydroxybenzylaldehyde 
• 883744-94-3 4-methoxy-benzo[1,3,2]dioxaborol-2-ol 
• 68-12-2 N,N-dimethyl-formamide 
• 85698-99-3 2-hydroxy-3,4-bis(methoxymethoxy)benzaldehyde 

Downstream Products

• 886747-62-2 trans-3,4'-dihydroxy-2',3',5-trimethoxystilbene 
• 883744-95-4 4-(difluoromethoxy)-3-hydroxy-2-methoxy-benzaldehyde 

Relevant academic research and scientific papers

Synthetic methods for phoyunbenes A-D and thunalbene

Invented is a method for synthesizing thunalbene and phoyunbenes A-D via a Horner-Wadsworth-Emmons (HWE) reaction in a simple and effective way. The compounds of the present invention have shown anti-inflammatory effects in RAW-264.7 macrophage which is induced by lipopolysaccharide.

Syntheses of phoyunbenes A-D and thunalbene for their anti-inflammatory evaluation

Simple and efficient first syntheses of phoyunbenes A-D and thunalbene have been developed using Horner- Wadsworth-Emmons reaction as a key step. Later, their anti-inflammatory effects were investigated in lipopolysaccharide-induced RAW-264.7 macrophages. The results revealed that phoyunbenes A-D and thunalbene showed weak inhibitory activities without cytotoxicity on the production of nitric oxide (NO) which is an important inflammatory mediator.

N-(3,5-DICHLOROPYRIDIN-4-YL)-2,4,5-ALKOXY AND 2,3,4-ALKOXY BENZAMIDE DERIVATIVES AS PDE-IV (PHOPHODIESTERASE TYPE-IV) INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES SUCH AS ASTHMA

The present invention relates to benzamide derivatives, which can be used as selective inhibitors of phosphodiesterase (PDE) type IV, having the structure of Formula (I), its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers of N-oxides wherein R1 is hydrogen, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroaryl, heterocyclyl, aralkyl, heterocyclylalkyl, heteroarylalkyl or cycloalkylalkyl; R2 is aryl, heteroaryl, heterocyclyl of cycloalkyl; and R3 is alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroaryl, heterocyclyl, aralkyl, heterocyclylalkyl, heteroarylalkyl or cycloalkylalkyl. Compounds disclosed herein can be useful in the treatment of inflammatory diseases, AIDS, asthma, arthritis, bronchitis, chronic obstructer pulmonary disease (COPD), psoriasis, allergic rhinitis, shock, atopic dermatitis, Crohn’ s disease, adult respiratory distress syndrome (ARDS), eosinophilic granuloma, allergic conjunctivitis, osteoarthritis and ulcerative colitis.

Effects of electron-withdrawing substituents on DPPH radical scavenging reactions of protocatechuic acid and its analogues in alcoholic solvents

The DPPH (2,2-diphenyl-1-picrylhydrazyl) radical scavenging activity of protocatechuic acid (3,4-dihydroxybenzoic acid) and its related catechols was examined. Compounds possessing strong electron-withdrawing substituents showed high activity. NMR analysis of the reaction mixtures of catechols and DPPH radical in methanol showed the formation of methanol adducts. The results suggest that high radical scavenging activity of catechols in alcohol is due to a nucleophilic addition of an alcohol molecule on o-quinones, which leads to a regeneration of a catechol structure. Furthermore, the radical scavenging activity in alcohols would largely depend on the electron-withdrawing/donating substituents, since they affect the susceptibility toward nucleophilic attacks on o-quinone.